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Abstract
Angiotensin II (AII) type I (AT1) receptor blockers are a 
well known group of drug that indicated principally for the 
treatment of hypertension as well as for the protection of 
kidney function in diabetic patients. Telmisartan is a highly 
selective angiotensin receptor blocker, and the favourable 
tolerability profile of telmisartan combined with its long 
elimination half- life ensure the drug provides pronounced 
reductions in blood pressure (BP) across the entire 24-
hour dosage interval. There is relatively very little data and 
information available to reveal renoprotective activity of 
telmisartan in nondiabetic low grade albuminuric Kurd 
hypertensive patients. Our study explores the effect of 
telmisartan on mean arterial blood pressure and it also sheds 
more light on its crucial role in lowering albumin: creatinine 
ratio in Kurd patients. The results of our study demonstrate 
that telmisartan reduces mean arterial blood pressure 
significantly, furthermore the study had explained a significant 
reduction in albuminuria at the second month of treatment 
which is regarded as a positive sign of renoprotection.
Key words:  ARBs; Albuminuria; Creatinine; 
Hypertension; Kurd race; Renal protection; Telmisartan 
Musl ih ,  A.  I .  (2014) .  Potent ia l  Reno-Protect ive Effects  of 
Telmisartan in Kurd Non-Diabetic Hypertensive Patients in 
Hawler City. Advances in Natural Science, 7 (1), 12-17. Available 
from: http://www.cscanada.net/index.php/ans/article/view/4349 
DOI: http://dx.doi.org/10.3968/4349
INTRODUCTION
Albuminuria (proteinuria) is well established to be a 
sensitive indicator of kidney disease (Yee et al., 2011), 
and its test is a powerful tool to screen individuals with 
chronic conditions such as hypertension and diabetes who 
are at high risk for renal damage (Özyilmaz, Bakker, de 
Zeeuw, de Jong, & Gansevoort, 2010), which means that 
the kidneys are not capable to retain or reabsorb filtered 
proteins back to the blood stream (Nordquist, Brown, 
Fasching, Persson, & Palm, 2009). Albuminuria most 
often occurs either when the glomerulus and/or renal 
microtubules are damaged (Satchell & Breat, 2009).
Increasing amounts of the albumin in urine is the 
reflection of more advanced renal failure (Ruilope & 
Bakris, 2011).
Creatinine a by-product of body metabolism is 
ordinarily excreted into the urine at a constant rate. Its 
measurement is used as a dependable factor in random 
urine samples (Brault & Terjung, 2003). Multi scientific 
centres have stated a preference for the microalbuminuria/
creatinine ratio (ACR) calculation for screening for 
albuminuria (Sarafidis et al., 2007). Protein:creatinine 
ratio in spot morning urine samples is a precise indicator 
of proteinuria and a reliable predictor of disease in non-
diabetic patients with chronic nephropathies (Guy, 
Borzomato, Newall, Kalra, & Price, 2009).
Reduction in both proteinuria and the rate of decline 
of glomerular filtration rate in chronic renal non 
diabetic diseases is mainly targeted by pharmacological 
blockade of the rennin-angiotensin-aldosterone system 
(RAAS) a principal therapy (Lizakowski et al., 2012; 
Muslih, 2012). In the chronic kidney disease (CKD) 
the presence of vascular dysfunction is documented 
(Loriga, Carru, Zinellu, Milia, & Satta, 2011). The 
presence of indistinctive risk factors such as proteinuria 
and vascular dysfunction, contribute to the excess of 
cardiovascular events (CVE) that characterizes chronic 
proteinuric nephropathy (Hirsch, 2008). Angiotensin II 
is a naturally occurring hormone that constricts blood 
and produces higher blood pressure (Redding et al., 
2010). Insufficient suppression of RAAS involved in 
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the development of higher arterial pressure (Rahmoni, 
Correia, Haynes, & Mark, 2005). Prolonged course of 
treatment with several angiotensin converting enzyme 
inhibitors (ACEIs) has been shown to decrease the risk 
of renal disease in diabetic patients (Iqbal & Shah, 2011). 
As well the use of angiotensin receptor blockers (ARBs) 
has beneficial effects on renal function (Hunt et al., 2009). 
Patients unable to tolerate ACEIs because of angioedema 
and cough (Kloth & Lane, 2011), the newer class of 
antihypertensive medication ARBs have shown advantage 
by minimizing hospital admissions and mortality (Powers 
et al., 2012). Compared with lisinopril, telmisartan is 
associated with a significant lower incidence of persistent, 
dry cough (Sharpe, Jarvis, & Goa, 2001). ARBs have 
a benefit parallel to that of ACEIs during treatment of 
patients complain from left ventricular dysfunction 
(Savelieva, Kakouros, Kourliouros, & Camm, 2011) 
posterior to myocardial infarction (MI). Telmisartan has 
a unique profile among ARBs, with a high lipophilicity 
(Burnier & Maillard, 2009), a long duration of receptor 
binding conferring 24-hour coverage of blood pressure 
(BP) control from a single daily dose (Song & White, 
2001), a high affinity for the angiotensin II type 1 receptor 
(Kakuta, Sudoh, Sasmata, & Yamagishi, 2005) and a 
long plasma half life (Zheng, Lin, & Shi, 2010). Many 
studies show that telmisartan is more effective than sub 
maximal dosages of losartan and valsartan (Fogari et 
al., 2012). An important characteristic feature is that 
telmisartan (amongst other ARBs) is a partial PPARγ 
agonist, a nuclear transcription factor that plays a role 
in the regulation of glucose and lipid metabolism, with 
this effect being independent of the BP lowering effects 
induced by AT1 antagonism (Yamagishi, Motsui, & 
Nakamura, 2008).
In spite of growing number of studies concerning 
pharmacological profile of ARBs, we find limited 
information about the renoprotective effect in patients 
with impaired renal function in nondiabetic hypertensive 
patients.
The aim of the study is to answer the following 
question: Does ARB (telmisartan) treatment exert 
renoprotective effects in addition to and at least in part 
independent of blood pressure reducing? To address the 
question, treatment was initiated in Kurd nondiabetic 
hypertensive patients and followed up over 6 months of 
treatment.
1.  MATERIALS AND METHODS
Subjects were recruited from Kurd patients with 
hypertension, 25 years or older, who visited the 
Educational Rizgary Hospital/Hawler between January 
2009 to July 2009 and with the participation of 47 patients 
afflicted with hypertension and on the basis of inclusion 
and exclusion criteria of the project (inclusion criteria: 
propensity to cooperation, affliction with hypertension, 
and exclusion criteria: patients have no other chronic 
disease and/or they are put on medicaments other than 
telmisartan. All the patients were informed of the aim 
of the study, and the potential effects of the procedure. 
The study was approved by the ethics committee of the 
Educational Rizgary Hospital/Department of Internal 
Medicine, and the study was conducted in accordance 
with the Declaration of Helsinki. All the patients signed a 
consent form approved by the ethics committee before the 
operation. Patients were allocated to receive telmisartan 80 
mg/day, serum creatinine was measured before treatment 
and after 10 days to detect the difference between the two 
readings which was found to be less than 20%-30% over 
baseline value to all patients, based on this we can rule 
out any potentiality of precipitation of unilateral/bilateral 
artery stenosis (Hackam, Spence, Garg, Textor, 2007; 
Cianci, Martina, Borghesi, di Donato, Polidori, Lai, Ascoli, 
de Francesco, Zaccaria, Gigante, Barbano, 2011). 
ACR was determined from a single morning urine 
sample that each patient delivered to the laboratory, and 
used to categorize subjects as follows: normoalbuminuria 
(ACR˂30 mg/g), microalbuminuria (ACR˂30-299 mg/g), 
macroalbuminuria (ACR˃300 mg/g) (American Diabetes 
Association, 2004; Krimholtz, Karalliedde, Thomas, 
Bilous, Viberti, 2005). Glucose or contamination with 
bacteria does not affect the estimation of albumin. For 
each patient albuminuria was divided by urine creatinine 
to obtain the ACR which is expressed as mg/g, as follow:
Urine albu min(mg/dl)
Urine creatinine(g/dl) = ACR (mg/g) (1)
The urine albumin concentration was measured using a 
competitive immunoassay (Immulite®, DPC, Los Angeles, 
CA, USA). Urinary creatinine level was analyzed by the 
Jaffe reaction using the kits available inside the country.
1.1  Parameters Measured
Blood pressure was detected by two measurements in the 
sitting position after 5 minutes of taking rest, applying 
Korotkoff and Riva-Rocci technique (Brien, 2008; 
Shimizu & Kario, 2008). All the measurements were made 
by the same investigators on the patients dominant arm at 
8:00 am: 11:00 am, mean arterial pressure was calculated 
according to:
(Systolic pressure+2)*Diastolic pressure
3  (2)
1.2  Statistical Analysis
Results presented as mean+SEM. Paired Students t-test 
was used to analyze differences in variables before and 
after treatment. Comparison between different groups was 
conducted using one-way ANOVA followed by a Student-
Newman-Keuls method. P-values<0.05 were considered 
statistically significant. The study data were analyzed by 
use of SPSS statistical software version 18.
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2.  RESULTS
Study results as in Table 1 includes two parts:
a. The figures demonstrate effects of telmisartan 80mg 
on albumin:creatinine ratio in non diabetic essential 
hypertensive patients. The level of ACR significantly 
decreased starting from the second month of the starting 
of the treatment compared to baseline time, while it is 
significantly decreased to below the normal range after 
6 months of treatment. ACR decreased from 84±12.2 to 
28.4±3.8 (p<0.05).
b. Reduction effect of telmisartan 80mg on blood 
pressure. Mean arterial pressure significantly (MAP) 
decreased after 1 month of treatment compared to 
baseline time. While treatment for 6 months significantly 
decreased MAP to below the normal blood pressure level, 
MAP decreased from 146±3.1mmHg to 101±1.1 mmHg 
(p<0.05).
Table 1
Decreas ing  Ef fec t s  o f  Te lmisar tan  80mg on 
Albuminuria and Mean Arterial Pressure in Patients 
With Kurd Non-Diabetic Hypertensive Patients
Time 
(month)
Albumine: creatinine ratio 
(ACR) mg/g
Mean Arterial Pressure 
(MAP) mmHg
mean SEM mean SEM
Baseline 84 12.2 146 3.1
1 80 11.3 134* 2.9
2 73.3* 9.1 125* 2
3 61.5* 7.3 118* 1.7
4 47.1* 6.4 111* 1.5
5 38.7* 5.2 107* 1.2
6 28.4*. 3.8 101* 1.1
Note. Values are mean±SEM; n=47. P<0.05
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Figure 1
Impact of Telmisartan 80 mg-Based Regimen on the 
Rate of Reduction in Mean Arterial Pressure in Kurd 
Non-Diabetic Hypertensive Patients
3.  DISCUSSION
The overwhelming body of evidence has shown that 
effective control of blood pressure (BP) reduces 
cardiovascular (CV) and renal risk in patients afflicted 
with hypertension (Mancia & Corrao, 2009). There are 
several mechanisms whereby activation of the RAS 
has been shown to play a role in the pathogenesis of 
renal disease (Rao, 2011). As the inhibition of Renin 
angiotensin system (RAS) has reducing effect on BP, 
it also in a different situation and according to recent 
studies exerts a renoprotective effect through reducing 
proteinuria.Increasing evidence indicates that the 
inhibition of RAS may exert a renoprotective effect that 
is independent of its effect on blood pressure reduction 
(Beri, 2009). RAS blockers [angiotensin converting 
enzyme inhibitors (ACEIs) and angiotensin II receptor 
blockers (ARBs)] are well recognized, effective 
antihypertensive agents that exert their BP lowering effect 
through diverse pathways at various levels of the RAS 
(Verdecchia, Gentile, Angeli, & Reboldi, 2012). In the 
past two decades RAS inhibitors have become a building 
block for the treatment of hypertension. Angioneurotic 
odema and cough are amongst the most occurrence side 
effects associated with ACEIs, but in present study we 
did not find such association of cough and telmisartan. 
Furthermore inhibitors of RAS have been used in a wide 
manner in patients with renal disease as it is reported that 
the agents have antiproteinuric effect that is independent 
of the blood pressure lowering action (Bianchi et al., 
2006) in another words RAS blockers that reduce BP, 
also reduce both proteinuria and do lessen glomerular 
filtration rate in chronic renal non diabetic diseases. 
Also it is observed by many researchers that proteinuria 
reducing therapies (ACEIs & ARBs) delay progression 
to diabetes (Akbari et al., 2009). Analytical data from 
clinical studies identify that ARBs may be more effective 
than other ACEIs or β blockers in stroke prevention. 
ARBs in contrast to ACEIs which do not produce dry 
cough, are increasingly used as antihyperternsive agents 
(White, Lacourciere, & Davidai, 2004).
The albumin to creatinine ratio (ACR) in a single 
untimed urinary specimen is a reflection of urinary 
albumin excretion and is increasingly being accepted as 
a marker that predicts several important health outcomes, 
including hypertension, kidney failure, cardiovascular 
events and mortality (Masson et al., 2010). Published 
data have shown that calculation of an albumin/creatinine 
ratio (ACR) in a spot urine sample has reasonable rate of 
sensitivity and specificity (Tuncel et al., 2004).
People who have consistently detectable amounts 
of albumin in their urine (microalbuminuria) have an 
increased risk of developing a progressive kidney failure 
and cardiovascular in the future. The presence of albumin 
in the urine (albuminuria) has been shown to be a sensitive 
indicator of kidney disease in patients with diabetes and 
with hypertension.
High systemic blood pressure leads to increased 
intraglomerular pressure, which in turn brings about 
mesangial cell hypertrophy and extracellular matrix 
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production, thickening of basement membrane and 
production of growth factor (Russo et al., 2008). Therefore, 
decrement of BP is necessary to prevent progression of 
renal abnormalities (American Diabetes Association, 
2007; Mancia et al., 2011), accordingly, reduction in BP 
is observed as subsidiary factor that prevent pregression 
of renal abnormalities The present study confirms the 
antiproteinuric performance of antihypertensive drug 
telmisartan and provides an impressive and well-tolerated 
remedy of hypertension with significantly less likely to 
account for persistent dry cough than other ACEIs in 
patients with essential hypertension. The reduction in ACR 
level appeared clearly on Kurd patients after 2 and 3 months, 
a conclusion that is close to the results of many researchers 
(Ninomiy et al., 2009). The mechanisms mentioned 
above could be regarded as pathways demonstrating 
antialbuminuric effects of the drug. The results also shows 
efficacy of telmisartan to decrease significantly mean arterial 
pressure, a result which agree with other studies performed 
by many co-workers (Tobe et al., 2011).
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